Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.
Bibliographic record
Abstract
14 Background: Abiraterone acetate (AA), a prodrug of abiraterone, which is a selective androgen biosynthesis inhibitor, prolongs overall survival (OS) in mCRPC pts and is approved for use in this population. An exploratory analysis was conducted to determine the impact of prior endocrine therapy on clinical benefit of AA in COU-AA-302, a randomized phase 3 study of pts with chemotherapy-naive mCRPC. Methods: 1,088 pts (testosterone < 50 ng/dL; receiving continuous gonadotropin-releasing hormone [GnRH] agonist if not orchiectomized) were randomized 1:1 to AA (1 g) + prednisone (P) (5 mg BID) or placebo + P alone. rPFS and OS were co-primary end points. rPFS was defined as time to first occurrence of bone scan progression by PCWG2 criteria, progression by CT/MRI by modified RECIST 1.0 criteria, or death, whichever came first. Comparison of the treatment effect on rPFS (investigator review at 55% of OS events) was made for the subgroups above or below the median duration of prior endocrine therapy in 2 categories: either prior GnRH agonist or prior antiandrogens. Cox model was used to obtain the HR and associated 95% CI with statistical inference by log rank statistic. Results: Most pts received prior GnRH agonists and antiandrogens (Table). rPFS was significantly more favorable with AA than P irrespective of the median duration of prior GnRH agonist or antiandrogen therapy. Increased median rPFS was observed in pts with longer prior exposure to GnRH agonists or antiandrogens comparing within both AA and P treatment groups. Conclusions: As shown in this COU-AA-302 exploratory analysis, duration of prior endocrine therapy, as analyzed after the onset of mCRPC, does not appear to impact clinical benefit of AA in pts with chemotherapy-naive mCRPC. Clinical trial information: NCT00887198. [Table: see text]
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".